GLX Analytix

Utilising the potential of digitalisation  

By utilising the potential of digitalisation gives unique opportunities to fundamentally improve patient lives. This goal and vision of potential is shared by the Copenhagen based biomedical startup, GLX Analytix. The company was founded in 2019 by two neuroscientists with extensive know-how on disease research in humans. 

Early Detection Is Key
GLX Analytix’s focus is among others on multiple sclerosis, a chronic demyelinating, autoimmune disease that affects millions of people world-wide and unfortunately, its prevalence is increasing. Moreover, the disease is highly unpredictable, and patients respond differently to different therapies. Today there is only non-curative, life-long and side-effect-prone treatments which highlight the need for improved early disease detection and effective treatment monitoring.

Consequently, GLX Analytix works on developing the first non-invasive and cost-effective blood test for disease activity in multiple sclerosis patients. This could be part of the standard care guidelines for diagnosis, prognosis and treatment response in challenging neuroinflammatory and neurodegenerative diseases. Moreover, it will enable early detection and continuous monitoring of the patients.

Attention is raised
GLX Analytix is well on their way with their research and have established numerous collaborations. Excitingly, in late 2019 they were awarded the Roche Future X Healthcare StartUp Award. Moreover, they recently reached out to Nordic Innovators for support on an InnoBooster grant application. In February 2020, GLX Analytix was successfully awarded the InnoBooster grant. We anticipate more success will come their way.